Возможности таргетной терапии метастатического колоректального рака с гиперэкспрессией HER2: клинический случай

СтатьяМЕД СОВЕТ. 2019; № 19: 126–131. DOI:10.21518/2079-701X-2019-19-126-131

Качмазов А.А.^[1]

Болотина Л. В.^[1]

Корниецкая А.Л.^[1]

Устинова Т.В.^[1]

Толстов В.А.^[1]

Феденко А.А.^[1]

^[1]Национальный медицинский исследовательский центр радиологии (Москва)

химиотерапия

таргетная терапия

трастузумаб

колоректальный рак

HER2

Новообразования

Трастузумаб

Каприн А.Д., Старинский В.В. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). P. 250. Режим доступа: http://www.oncology.ru/service/statistics/malignant_tumors/2017.pdfhttp://www.oncology.ru/service/statistics/malignant_tumors/2017.pdf

Rakha E.A. et al. Updated UK Recommendations for HER2 assessment in breast cancer. Journal of Clinical Pathology. 2015;68(2):93–99. doi: 10.1136/jclinpath-2014-202571..
DOI: 10.1136/jclinpath-2014-202571

Rüschoff J. et al. HER2 testing in gastric cancer: a practical approach. Modern Pathology. 2012;25(5):637–650. Available at: https://www.nature.com/articles/modpathol2011198.https://www.nature.com/articles/modpathol2011198

Kim E.K. et al. The frequency and clinical impact of HER2 alterations in lung adenocarcinoma. PLoS ONE. 2017;12(2):e0171280. doi: 10.1371/journal.pone.0171280..
DOI: 10.1371/journal.pone.0171280

Schwartz R.S., Erban J.K. Timing of Metastasis in Breast Cancer. New England Journal of Medicine. 2017;376(25):2486–2488. doi: 10.1056/NEJMcibr1701388..
DOI: 10.1056/NEJMcibr1701388

Liang J. et al. Clinicopathological and prognostic significance of HER2 overexpression in gastric cancer: a meta-analysis of the literature. Tumor Biol. 2014;35(5):4849–4858. Available at: https://link.springer.com/article/10.1007[%]2Fs13277-014-1636-3.https://link.springer.com/article/10.1007[%]2Fs13277-014-1636-3

Ettl T. et al. Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer. British Journal of Cancer. 2012;106(4):719–726. Available at: https://www.nature.com/articles/bjc2011605.https://www.nature.com/articles/bjc2011605

McKay J.A. et al. c-erb B-2 is not a major factor in the development of colorectal cancer. Br J Cancer. 2002;86(4):568–573. Available at: https://www.nature.com/articles/6600127.https://www.nature.com/articles/6600127

Song Z. et al. Immunohistochemical results of HER2/neu protein expression assessed by rabbit monoclonal antibodies SP3 and 4B5 in colorectal carcinomas. Int J Clin Exp Pathol. 2014;7(7):4454–4460. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25120833/https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25120833/

Bufill J.A. Colorectal Cancer: Evidence for Distinct Genetic Categories Based on Proximal or Distal Tumor Location. Ann Intern Med. 1990;113(10):779. doi: 10.7326/0003-4819-113-10-779..
DOI: 10.7326/0003-4819-113-10-779

Marshall J. et al. Molecular variances between rectal and left-sided colon cancers. JCO. 2017;35(4_suppl.):522–522. doi: 10.1200/JCO.2017.35.4_suppl.522..
DOI: 10.1200/JCO.2017.35.4_suppl.522

Bertotti A. et al. A Molecularly Annotated Platform of Patient-Derived Xenografts («Xenopatients») Identifies HER2 as an Effective Therapeutic Target in CetuximabResistant Colorectal Cancer. Cancer Discov. 2011;1(6):508–523. doi: 10.1158/2159-8290.CD-11-0109..
DOI: 10.1158/2159-8290.CD-11-0109

Richman S.D. et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. The Journal of Pathology. 2016;238(4):562–570. Available at: https://onlinelibrary.wiley.com/doi/full/10.1002/path.4679.https://onlinelibrary.wiley.com/doi/full/10.1002/path.4679

Valtorta E. et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol. 2015;28(11):1481–1491. doi: 10.1038/modpathol.2015.98..
DOI: 10.1038/modpathol.2015.98

Conradi L.-C. et al. Frequency of HER-2 Positivity in Rectal Cancer and Prognosis. The American Journal of Surgical Pathology. 2013;37(4):522. doi: 10.1097/PAS.0b013e318272ff4d..
DOI: 10.1097/PAS.0b013e318272ff4d

Osako T. et al. Immunohistochemical Study of c-erbB-2 Protein in Colorectal Cancer and the Correlation with Patient Survival. OCL. 1998;55(6):548–555. doi: 10.1159/000011911..
DOI: 10.1159/000011911

Kapitanovic S. et al. The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology. 1997;112(4):1103–1113. Available at: https://www.draganprimorac.com/wp-content/uploads/2012/08/Theexpression-of-HER2-neu-gene-Gastroenterology-1997.pdf.https://www.draganprimorac.com/wp-content/uploads/2012/08/Theexpression-of-HER2-neu-gene-Gastroenterology-1997.pdf

Sartore-Bianchi A. et al. Dual-targeted therapy with trastuzumab and lapatinib in treatmentrefractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. The Lancet Oncology. 2016;17(6):738–746. Available at: https://linkinghub.elsevier.com/retrieve/pii/S1470204516001509.https://linkinghub.elsevier.com/retrieve/pii/S1470204516001509

Hainsworth J.D. et al. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. Journal of Clinical Oncology. 2018;(36):536–544. doi: 10.1200/JCO.2017.75.3780..
DOI: 10.1200/JCO.2017.75.3780

Ramanathan R.K. et al. Low overexpression of HER-2/PPPNeu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin®) and irinotecan as therapy. A phase II trial. Cancer investigation. 2004;22(6):858–865. Available at: https://www.tandfonline.com/doi/full/10.1081/CNV-200039645.https://www.tandfonline.com/doi/full/10.1081/CNV-200039645

Rubinson D.A. et al. Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: Results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. Invest New Drugs. 2014;32(1):113–122. Available at: https://link.springer.com/article/10.1007[%]2Fs10637-013-9956-5.https://link.springer.com/article/10.1007[%]2Fs10637-013-9956-5

Clark J., Niedzwiecki D., Hollis D. Phase-II trial of 5-fluororuacil (5-FU), leucovorin (LV), oxaliplatin (Ox), and trastuzamab (T) for patients with metastatic colorectal cancer (CRC) refractory to initial therapy. Onkologie. 2003;23:13–46.

Siena S. et al. HER2 amplification as a ‘molecular bait’ for trastuzumab-emtansine (T-DM1) precision chemotherapy to overcome antiHER2 resistance in HER2 positive metastatic colorectal cancer: The HERACLES-RESCUE trial. JCO. 2016;34(4_suppl.):TPS774–TPS774. doi: 10.1200/jco.2016.34.4_suppl.tps774..
DOI: 10.1200/jco.2016.34.4_suppl.tps774

Strickler J.H. et al. A phase II, open label study of tucatinib (ONT-380) combined with trastuzumab in patients with HER2+ metastatic colorectal cancer (mCRC)(MOUNTAINEER). JCO. 2017;35(15_suppl.):TPS3624–TPS3624. doi: 10.1200/JCO.2017.35.15_suppl.TPS3624..
DOI: 10.1200/JCO.2017.35.15_suppl.TPS3624

Diaz L.A. et al. Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC. JCO. 2017;35(15_suppl.):3071–3071. doi: 10.1200/JCO.2017.35.15_suppl.3071..
DOI: 10.1200/JCO.2017.35.15_suppl.3071

Overman M.J. et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. The Lancet Oncology. 2017;18(9):1182–1191. Available at: https://linkinghub.elsevier.com/retrieve/pii/S1470204517304229.https://linkinghub.elsevier.com/retrieve/pii/S1470204517304229

Corcoran R.B. et al. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600EMutant Colorectal Cancer. Cancer Discov. 2018;8(4):428–443. doi: 10.1158/2159-8290.CD-17-1226..
DOI: 10.1158/2159-8290.CD-17-1226

Kopetz S. et al. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. J Clin Oncol. 2015;33(34):4032–4038. doi: 10.1200/JCO.2015.63.2497..
DOI: 10.1200/JCO.2015.63.2497

Gelsomino F., Barbolini M., Spallanzani A., Pugliese G., Cascinu S. The evolving role of microsatellite instability in colorectal cancer: A review. Cancer Treat Rev. 2016;(51):19-26. doi: 10.1016/j.ctrv.2016.10.005..
DOI: 10.1016/j.ctrv.2016.10.005

Brim H., Mokarram P., Naghibalhossaini F., Saberi-Firoozi M., Al-Mandhari M., Al-Mawaly K., et al. Impact of BRAF, MLH1 on the incidence of microsatellite instability high colorectal cancer in populations based study. Mol Cancer. 200821;7:68. doi: 10.1186/1476-4598-7-68..
DOI: 10.1186/1476-4598-7-68

Язык текста: Русский

ISSN: 2079-701X